title: [News in blood pressure in 2015].
abstract: In this short review, we present 4 studies published in 2014-2015 which appear to important for clinicians. The results of the SPRINT trial are challenging the target systolic blood pressure (BP) to be achieved in non-diabetic hypertensive. It shows that a target BP <120 mmHg provides clear mortality and morbidity advantages over a <140 mmHg target. The PATHWAY2 and 3 studies reemphasize the important role of potassium sparing diuretics in patients with resistant hypertension and in patients with metabolic syndrome. At last the DENERHTN study conducted in France suggests that renal denervation is not dead and that additional studies are needed to position this technique in management of resistant hypertension.
authors.forename: Fatma
authors.initials: F
authors.lastname: Megdiche
authors.forename: Edward
authors.initials: E
authors.lastname: Pivin
authors.forename: Grégoire
authors.initials: G
authors.lastname: Wuerzner
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D003714:Denervation / Q000379:methods; D062865:Diuretics, Potassium Sparing / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D024821:Metabolic Syndrome / Q000188:drug therapy
chemical_list: D000959:Antihypertensive Agents; D062865:Diuretics, Potassium Sparing